What is the recommended antiplatelet and anticoagulation regimen after transcatheter aortic valve implantation (TAVI)?

Post-TAVI Antithrombotic Protocol

For patients without an independent indication for anticoagulation (no atrial fibrillation, no venous thromboembolism), aspirin 75-100 mg daily alone is the recommended strategy after TAVI. 1

Primary Recommendation: Aspirin Monotherapy

The 2020 ACC/AHA Guidelines provide a Class 2a recommendation for aspirin 75-100 mg daily as monotherapy in TAVI patients without other indications for oral anticoagulation 1. This represents the most straightforward, evidence-based approach that balances thrombotic protection against bleeding risk.

Supporting Evidence

Recent network meta-analyses consistently demonstrate that single antiplatelet therapy (SAPT) provides the optimal risk-benefit profile:

• Mortality benefit: SAPT reduces all-cause mortality compared to dual antiplatelet therapy (DAPT) and shows superior ranking (SUCRA 85.0%) 2
• Bleeding reduction: SAPT reduces major bleeding by 44-80% compared to DAPT, direct oral anticoagulants, or combination therapy 3, 4
• Equivalent thrombotic protection: No significant differences in stroke, myocardial infarction, or cardiovascular mortality between SAPT and more intensive regimens 3, 2

Alternative Regimens (Lower Priority)

Dual Antiplatelet Therapy (DAPT)

DAPT (aspirin 75-100 mg + clopidogrel 75 mg) may be reasonable for 3-6 months in patients at low bleeding risk 1, though this carries a Class 2b recommendation (weaker evidence). The 2017 ESC/EACTS Guidelines similarly suggest DAPT for 3-6 months followed by single antiplatelet therapy 5.

Clinical context: Consider DAPT only in younger patients with high thrombotic risk (recent acute coronary syndrome, complex coronary anatomy, high-risk procedural features) AND demonstrably low bleeding risk. This is not the default strategy.

Warfarin Monotherapy

Warfarin (INR target 2.5) may be reasonable for at least 3 months post-TAVI in patients at low bleeding risk 1, though this also carries a Class 2b recommendation. Some observational data suggest warfarin may reduce valve gradient increases suggestive of leaflet thrombosis 1.

Important caveat: This is not standard practice and should be reserved for highly selected cases where subclinical leaflet thrombosis is a particular concern.

Contraindicated Strategies

Low-dose rivaroxaban (10 mg daily) plus aspirin is contraindicated (Class 3: Harm) in TAVI patients without other indications for anticoagulation 1. The GALILEO trial demonstrated increased mortality and bleeding with this regimen 1.

Patients WITH Indication for Anticoagulation

Atrial Fibrillation or Other Anticoagulation Indications

Use oral anticoagulation alone without adding antiplatelet therapy in patients with atrial fibrillation, venous thromboembolism, or hypercoagulable states 5.

Key evidence:

• Warfarin monotherapy shows similar stroke rates but significantly reduced bleeding (OR 0.49) compared to warfarin plus antiplatelet therapy 4
• Network meta-analyses rank oral anticoagulation alone as safer than combination therapy 4

Emerging data: The 2026 ACASA-TAVI trial demonstrated that NOAC monotherapy (factor Xa inhibitor) reduced leaflet thrombosis by 45% compared to aspirin (16.2% vs 28.6%, P=0.004) and was noninferior for bleeding/thromboembolism in selected patients aged 65-80 6. However, this represents investigational use in patients without traditional anticoagulation indications and is not yet guideline-endorsed.

Triple Therapy (Anticoagulation + DAPT)

If recent percutaneous coronary intervention necessitates DAPT in a patient requiring anticoagulation:

• Limit triple therapy to ≤1 month (maximum 6 months if very high ischemic risk outweighs bleeding risk) 5
• Transition to warfarin plus clopidogrel as soon as feasible 5
• Target INR in the lower therapeutic range (2.0-2.5) with time in therapeutic range >65-70% 5
• Avoid prasugrel or ticagrelor in triple therapy regimens 5

Practical Algorithm

1. Does the patient have AF, VTE, or other anticoagulation indication?

   • YES → Oral anticoagulation alone (warfarin or DOAC per AF guidelines)
   • NO → Proceed to step 2

2. Does the patient have recent ACS or PCI requiring DAPT?

   • YES → DAPT for indicated duration, then transition to aspirin alone
   • NO → Proceed to step 3

3. Default strategy: Aspirin 75-100 mg daily indefinitely

4. Consider DAPT for 3-6 months only if:

   • Age <75 years AND
   • High thrombotic risk features (complex anatomy, large valve size mismatch) AND
   • HAS-BLED score ≤2 (low bleeding risk)

Common Pitfalls

• Avoid reflexive DAPT: Historical practice patterns favored DAPT, but contemporary evidence strongly supports aspirin monotherapy for most patients
• Don't combine anticoagulation with antiplatelet therapy routinely: This dramatically increases bleeding without clear thrombotic benefit
• Never use rivaroxaban 10 mg + aspirin: This specific regimen is explicitly contraindicated
• Don't use DOACs for mechanical valves: While TAVI involves bioprosthetic valves, this remains a critical safety principle if mechanical valves are ever considered